--- title: "Weekly Recap | BEONE MEDICINES +6.54%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/296666356.md" description: "BEONE MEDICINES (6160.HK) closed the week at HK$228, up 6.54% over four trading sessions, outperforming the Hang Seng Index by roughly 4.35 percentage points. The rally showed a clear surge-and-retreat pattern. Monday (17 Aug) opened at HK$217 and edged up to 220.8. Tuesday (18 Aug) continued higher to 223.6. Wednesday (19 Aug) saw a gap-up open at HK$230, with the stock hitting an intraday high of 235.6 before retreating to close at 227.8." datetime: "2026-08-22T04:19:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296666356.md) - [en](https://longbridge.com/en/news/296666356.md) - [zh-HK](https://longbridge.com/zh-HK/news/296666356.md) generator: "portal-rs" --- # Weekly Recap | BEONE MEDICINES +6.54%, most brokers rate it buy ## The Week BEONE MEDICINES (6160.HK) closed the week at HK$228, up 6.54% over four trading sessions, outperforming the Hang Seng Index by roughly 4.35 percentage points. The rally showed a clear surge-and-retreat pattern. Monday (17 Aug) opened at HK$217 and edged up to 220.8. Tuesday (18 Aug) continued higher to 223.6. Wednesday (19 Aug) saw a gap-up open at HK$230, with the stock hitting an intraday high of 235.6 before retreating to close at 227.8. Thursday (20 Aug) was a narrow-range session, ending at 228. The weekly trading range was 8.85%, with average daily volume of about 4.85 million shares, roughly in line with the median — suggesting activity was steady rather than speculative. ## Key Events The week’s narrative centred on expanding global access to BRUKINSA® (zanubrutinib). On Tuesday (18 Aug), the company announced a renewed partnership with the BeOne Care Foundation and The Max Foundation to broaden access to BRUKINSA® for treating chronic lymphocytic leukaemia in low- and middle-income countries. The stock rallied for two straight sessions on the news, hitting a weekly high of 235.6 on Wednesday (19 Aug). The same day saw a broader advance in Hong Kong-listed biotech names, with innovative drug stocks attracting strong buying interest. On Thursday (20 Aug), the stock joined a group of biotech peers — including WuXi Biologics and WuXi AppTec — in hitting new highs during the session. Two routine regulatory filings were published after Thursday’s close. ## Analyst Ratings Broker coverage on the name remains broadly constructive. Of 18 analysts tracked, 14 rate the stock a ‘buy’ and 3 rate it ‘over’, with a single ‘hold’ rating and no ‘under’ or ‘sell’ calls. The consensus rating is ‘strong buy’, with a consensus target price of HK$263.47, implying a roughly 15.6% upside from the latest close of HK$228. Individual target prices range from HK$225.93 to HK$321.60, a wide spread that reflects genuine disagreement on the stock’s long-term value. Within the biotechnology sector, which covers 51 comparable companies, the stock ranks 4th by analyst conviction. ## The Week Ahead The BRUKINSA® access expansion in lower- and middle-income markets was the week’s headline story. Any follow-up on specific regions or implementation timelines would be a natural focal point for the market. More broadly, the biotech sector staged a broad rally this week; whether the rotation out of hardware tech and into biotech has legs will be a key theme to watch in the coming sessions. ## In Short BEONE MEDICINES outperformed this week on news of wider global access for its core product, pushing the stock near its historical highs. The analyst consensus is overwhelmingly positive, with a ‘strong buy’ rating and a target price that sits above the spot, though the wide spread of individual targets signals unresolved long-term valuation debates. On the latest trading day, large-lot money was a net buyer, but mid-lot funds turned net seller — a split that adds texture to the fund-flow picture. The stock trades at roughly 68x earnings and 10.4x book value, a premium tier that embeds high expectations. The tension this week is between a strong product narrative and supportive ratings on one side, and a demanding valuation with mixed fund flows on the other; the next catalyst likely hinges on tangible progress from the BRUKINSA® access programme. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) ## Related News & Research - [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md) - [BeOne Medicines and partners renew Brukinsa access programme for CLL](https://longbridge.com/en/news/296331290.md) - [GJF: Pension drives scalable, capital-light growth with strong SME focus and ambitious financial targets](https://longbridge.com/en/news/296927502.md) - [China Foods Posts Higher Interim Earnings Amid Margin Pressure and No Dividend](https://longbridge.com/en/news/296865772.md) - [REG - C&C Group Plc - Holding(s) in Company](https://longbridge.com/en/news/296912403.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**